- 2015- 2018
- 2010 - 2014
- 2005-2009
- 2001- 2004
- 1999 - 1996
2015- 2018
2018
August 3, 2018, “Biomolecular Computational Methods for Protein Engineering Against Aggregation and Other Molecular Liabilities,” Acceleron Pharma, Cambridge, MA.
May 30, 2018, “Continuous Lyophilization of Pharmaceutical Products in Unit Doses,” Hudson Valley LyoMac Webinair.
2017
December 7, 2017, “Enabling Developability via Molecular Modeling,” CDD for Biologics, Boston, MA.
December 1, 2017, “The Significance of Quantum Mechanics,” St. John’s College, Annapolis, MD.
October 17, 2017, “Biomolecular Computational Methods for Protein Engineering Against Aggregation and Other Molecular Liabilities”, Biovia Community Day, Cambridge, MA.
September 21, 2017, “Developability for Biologics and Approaches to Formulation Design,” Biologics, Modeling, and Informatics (BMI) Discussion Group, Cambridge, MA.
July 19, 2017, “Biopharmaceuticals and Continuous Manufacturing,” Senate Competitive Caucus, U.S. Senate, Washington D.C.
May 10, 2017, “New Continuous Crystallization Technologies for Small Molecule Pharmaceutical Manufacturing,” Vertex Pharmaceuticals, Boston, MA.
April 13, 2017, “Ethics and Engineering: How to Think About the Ethics of AI,” MIT Course 6 Super UROP, Cambridge, MA.
February 10, 2017, “New Technologies for Holistic Pharmaceutical Creation,” United States Pharmacopeia, Rockville, MD.
February 1, 2017, “New Technologies for Holistic Pharmaceutical Creation: Focus on 3D Printing,” Takeda, Zurich, Switzerland.
January 31, 2017, “Developability and Manufacturability in Pharmaceutical Creation,” Roche, Basel, Switzerland.
January 31, 2017, “Developability and Manufacturability in Pharmaceutical Creation,” Lonza, Basel, Switzerland.
2016
December 15, 2016, “Enabling Developability Via Molecular Modeling,” IBC Antibody Engineering & Therapeutics, San Diego, CA.
October 26, 2016, “Integrating Discovery, Development and Manufacturing in Pharmaceutical Creation,” University of Pennsylvania Department of Chemical and Biomolecular Engineering, Philadelphia, PA.
May 13, 2016, “Quantum Mechanics and Political Philosophy,” MIT Conference on Mastery of Nature, Cambridge, MA.
March 17, 2016, “Ethics in Engineering,” MIT Course 6 Super-UROP, Cambridge, MA.
2015
October 5, 2015, “New Technologies for Enabling Continuous Manufacturing,” PQRI Meeting, Bethesda, MD (plenary lecture)
September 16, 2015, “Rational Approaches for the Developability of Biotherapeutics” Boston University Department of Physical Chemistry, Boston, MA
September 7, 2015, “MIT’s Success at Teaching and Research,” National Polytechnic University, Yerevan, Armenia
June 4, 2015 “Continuous Processing in (Bio)Pharmaceutical Manufacturing,” Ipsen Corporation, Paris, FR
May 15, 2015 “Advanced Formulation, Stabilization, and Manufacturing of Therapeutic Antibodies” MassBiologics, Boston, MA
April 29, 2015 “Continuous Pharmaceutical Manufacture and Advances in Biopharmaceuticals Formulation” The Pall Corporation Technology Symposium, Cambridge, MA. (Keynote Address)
April 14, 2015 “Rational Approaches for the Development of Biotherapeutics,”4th International Symposium on Higher Order Structure of Protein Therapeutics, Boston, MA
March 27, 2015 “Molecular and Macroscopic Engineering of Small Molecular Crystallization,” Department of Mechanical and Chemical Engineering, ETH, Zurich, Switzerland
March 24, 2015 “Holistic Pharmaceutical Process Development,” Department of Mechanical and Chemical Engineering, ETH, Zurich, Switzerland
2010 - 2014
2014
Sept. 16, 2014 “Enabling Technologies for the Continuous Manufacturing of APIs: Continuous Crystallization” at FDA/PQRI Conference, Silver Spring, MD
June 10, 2014 “How ‘Continuous’ Manufacturing will Transform Biotherapeutic Manufacturing” The Annual Bio Manufacturing & Process Innovation Leaders Summit USA 2014 (MANU-BIO), Boston, MA (Keynote Address)
June 6, 2014 “Strategic Approaches for Understanding and Hindering Aggregation” IBC’s Protein Aggregation, Stability & Solubility Conference, San Francisco, CA (Keynote Address)
March 26, 2014 “Rational Approaches to Developability and Manufacturability” Accelyrs, Cambridge, MA
March 21, 2014 “Rational Approaches to Developability and Manufacturability” Bayer, Wuppertal, Germany
January 21, 2014 “Rational Approaches for Biologics and Small Molecule Pharmaceutical Development and Manufacturing” Columbia University, New York, NY
January 8, 2014 “Rational Approaches to Developability and Manufacturability” Pfizer, Cambridge, MA
2013
December 16, 2013 “Rational Approaches to Developability and Manufacturability”BMS, Devens, MA
November 7, 2013, “Recent Updates at the Novartis-MIT Center for Continuous Manufacturing”, FDA, Silver Spring, MD
November 5, 2013 “Transforming Manufacturing to “Continuous”: Flexible API and Final Dosage Form” ISPE Meeting, Washington, DC
October 21, 2013 “Transforming Small Molecule Pharmaceutical Manufacturing to Continuous and the Potential for Continuous Biologics Manufacturing,” Integrated Continuous Biomanufacturing, an ECI Conference, Barcelona, Spain (Keynote Address)
September 11, 2013 “Rational Approaches to Developability and Manufacturability,” Biogen Idec, Cambridge, MA
September 10, 2013 “Rational Approaches to Developability and Manufacturability,” Pfizer, Andover, MA
July 10, 2013 “What Molecular Modeling in Pharmaceutical Development Can Do for You,” BMS Symposium on Modeling, New Brunswick, NJ (Keynote Address)
June 27, 2013 “Capitalizing on Continuous Manufacturing,” 8th Global Pharma Manufacturing Summit, Boston, MA (Plenary Lecture)
June 12, 2013, “Transforming Small Molecule Pharmaceutical Manufacturing to Continuous and the Potential for Continuous Biologics Manufacturing,” Biomanufacturing Leaders Summit, Boston, MA (Keynote Address)
April 24, 2013 “From Molecular Computations to Continuous Manufacturing and Their Role in Shaping a Sustainable Future,” 9th European Congress of Chemical Engineering, The Hague, Netherlands (Plenary Lecture)
April 19, 2013 “Transforming Pharmaceutical Manufacturing Continuous: The Ultra Lean Way of Manufacturing,” Pharmintech, Bologna, Italy (Keynote Address)
March 26, 2013, “Rational Approaches to Developability for Stabilization Against Aggregation and Other Routes,” 6th Annual Proteins Conference, London, UK.
2012
November 15, 2012, “Rational Approaches to Developability, Formulation, and Design of Biobetters,” MIT Center for Biomedical Innovation: Biomanufacturing Summit, Cambridge, MA
November 14, 2012, “Advanced manufacturing for pharmaceuticals and the Novartis- MIT center for continuous manufacturing,” MIT ILP R&D Conference, Cambridge, MA
August 21, 2012, “Technical Update for the FDA on the Downstream Continuous Manufacturing Toolbox,” FDA, Cambridge, MA
May 5, 2012, “Rational Approaches to the Stabilization of Biologics: Incorporating Developability and Manufacturability,” Ispen, Milford, MA.
2011
November 18, 2011, “Protein Aggregation Modeling and Novel Excipients for Downstream Processing: Incorporating Rational Approaches to Developability and Manufacturability for Biotherapeutics,” BioMan, Cambridge, MA.
November 9, 2011, “Predication of Aggregation Prone Regions in Proteins: Incorporating Rational Approaches to Developability and Manufacturability for Biotherapeutics,” CASSS Symposium on Immunogenicity, Gaithersburg, MD
October 20, 2011, “Heterogeneous Crystallization of API’s on Excipients for “Continuous” Process and Product Design,” Peck Symposium at Purdue University, West Lafayette, IN
October 19, 2011, “Transforming Pharmaceutical Development and Manufacturing with Molecular Computations ,” AIChE Annual Symposium, CoMSEF Award, Minneapolis, MN
September 15, 2011, “Transforming Pharmaceutical Manufacturing, Continuous: The Ultra Lean Way of Manufacturing,” President Obama’s Advanced Manufacturing Partnership, Cambridge, MA
August 4, 2011 “Rational Approaches to Stabilization: Incorporating Developability in Discovery through Development Phases,” GSK, King of Prussia, PA
July 28, 2011 “Rational Approaches to Stabilization: Incorporating Developability in Discovery through Development Phases,” Pfizer Research, Cambridge, MA
July 21, 2011, “Molecular Modeling Approaches for Predicting The Stability of Biotherapeutics, Antibodies in Particular,” Colorado Protein Stability Conference , Breckenridge, CO
May 19, 2011, “Computational Approaches for Identifying Degradation “Hotspots”: Spatial Aggregation Propensity and Implementation in Pipeline Pilot,”Accelrys North America-UGM Conference, Newark, NJ
March 29, 2011, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization,” ACS, Anaheim, CA (Plenary Lecture)
March 15, 2011, “Transforming Pharmaceutical Manufacturing Continuous: The Ultra Lean Way of Manufacturing,” ISPE-NJ
2010
November, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” AAPS Annual Meeting, New Orleans, LA
October, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” PEGS Biotechnology conference, Hannover, Germany
September, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Ipsen Corporation, Milford, MA
September, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” IBC Protein Formulation Conference, Providence, RI
August, 2010, “Molecular Modeling for the Rational Control of Polymorphism and Morphology,” Sepracor Corporation, Marlborough, MA
July, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” MedImmune Corporation, Gaithersburg, MD
July, 2010, “Continuous Manufacturing: The Ultimate in Quality by Design,” Sepracor Corporation, Marlborough, MA
May, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Accelrys Annual International Conference, Boston, MA
April, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” ISPE Biotech Meeting, Cambridge, MA
April, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Merck, West Point, PA
March, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Genzyme, MA
March, 2010, “Molecular Modeling for the Rational Control of Polymorphism and Morphology,” Gilead Corporation, Foster City, CA
March, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Genentech, South San Francisco, CA
March, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Amgen, Thousand Oaks, CA
March, 2010, “Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization and Protein-Cosolute Interactions: A New Strategy of Molecular QbD,” Biogen-Idec, Cambridge, MA
2005-2009
2009
December, 2009, “Continuous Manufacturing of Small Molecule Pharmaceuticals,” Leaders for Global Manufacturing, MIT, Cambridge, MA
November, 2009, “Order parameter methods for reactions in complex systems,” Princeton Center for Theoretical Sciences, Department of Physics, Princeton, NJ
October, 2009, “Rational approaches to protein and antibody stabilization,” Schering- Plough, Elizabeth, NJ
September, 2009, “Rational approaches to protein and antibody stabilization,” Merck & Co., West Point, PA.
September, 2009, “Modeling of crystallization processes,” Merck Research Laboratories, Rahway, NJ.
September, 2009, “Rational approaches to pharmaceutical manufacturing,” Merck Research Laboratories, Rahway, NJ.
July, 2009, “Continuous manufacturing: the ultra lean way of manufacturing,” Biochemical Engineering XVI, Burlington, VT.
June, 2009, “Rational approaches to protein and antibody stabilization,” Bristol-Meyers Squibb, New Brunswick, NJ.
April, 2009, “Reactivity in complex systems,” University of Washington.
March, 2009, “Reactivity in complex systems,” North Carolina Theory Seminar.
February, 2009, “Reactivity in complex systems,” UCLA.
2008
September, 2008, “Continuous manufacturing of pharmaceuticals: the ultra lean way of manufacturing,” Global Pharmaceutical Manufacturing Summit, Chicago.
June, 2008, “Rational design of solvent formulations via molecular computations,” American Association of Pharmaceutical Science National Biotechnology Conference, Toronto, Canada.
March, 2008, “Frontiers in chemical reactivity and pharmaceutical manufacturing,” Department of Chemical Engineering, University of Puerto-Rico.
March, 2008, “Frontiers in chemical reactivity and pharmaceutical manufacturing,” Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana- Champaign.
2007
October, 2007, “Formulation approaches for the future,” IBC Life Sciences on Formulation Strategies for Protein Therapeutics, Hynes Convention Center, Boston, Keynote Address.
July, 2007, “Understanding reaction processes in complex media such as liquids,” Gordon Conference on the Chemistry of Liquids, Holderness School, New Hampshire
June, 2007, “Molecular Design of New Excipients for Large Molecule Stabilization,” AAP National Biotechnology Conference, San Diego, CA.
March, 2007, “Finding reactions coordinates for complex processes via likelihood maximization,” ACS Spring Meeting, Chicago, IL.
2006
November, 2006, “Understanding complex reaction processes,” Department of Chemical Engineering, University of Buffalo, Buffalo, New York.
July, 2006, “Molecular simulations of ice and gas hydrate nucleation,” Physics and Chemistry of Ice Conference, Bremerhaven, Germany, Keynote Address.
June, 2006, “Reaction coordinates from likelihood maximization,” U.S.-Poland Workshop on Nanoscience and Nanostructured Materials, Poznan, Poland.
June, 2006, “Understanding complex reaction processes with applications to pharmaceuticals and heterogeneous catalysis,” Department of Chemistry, University of Western Ontario, London, Ontario, Canada.
February, 2006, “Statistical physics applied to the development of biopharmaceuticals,” Department of Physics, University of Rome “La Sapienza,” Rome, Italy.
February, 2006, “Statistical physics applied to the development of biopharmaceuticals,” SISSA, International School for Advanced Studies, Trieste, Italy.
2005
September, 2005, “Molecular engineering of chemical systems,” Department of Chemical Engineering, Drexel University, Philadelphia, Pennsylvania.
September, 2005, “Molecular engineering of chemical systems,” Department of Chemical Engineering, Texas A&M, College Station, Texas.
September, 2005, “Reactivity in complex systems,” Meeting in honor of Michele Parrinello’s 60th Birthday, Agno, Switzerland.
July, 2005, “Molecular computational engineering: mechanism of methionine oxidation and rational design of additives for hindering aggregation,” Protein Stability Conference, Breckenridge, Colorado.
May, 2005, “Transition Path Sampling Calculations in Complex Systems or How Can We Find the Reaction Coordinate?” 2005 International Conference on Scientific Computation and Differential Equations (SciCADE), Nagoya, Japan.
March, 2005, “Molecular computations for predictions of clathrate-hydrate nucleation and phase-behavior of multi-component hydrates,” Hydrate Symposium at the American Chemical Society Spring Meeting, San Diego, California.
March, 2005, “Water structuring in phase transitions and in chemical reactions at sulfur sites in proteins,” Water: Structure, Dynamics and Reactions Across the Phase Diagram at the American Chemical Society Spring Meeting, San Diego, California.
2001- 2004
2004
July, 2004, “A unified approach for the nucleation of ice and ice-like systems in homogeneous and inhomogeneous environments,” Telluride Workshop on Studies of ice, icy particles, ice surfaces, and ice-adsorbate interactions: a molecular view,” Telluride, Colorado.
April, 2004, “Molecular analyses and design for the stabilization of therapeutic proteins,” Department of Chemical Engineering, Tufts University, Medford, Massachusetts.
April 2004, “Molecular analyses and design for the stabilization of therapeutic proteins,” Department of Chemistry, Boston University, Boston, Massachusetts.
March, 2004, “Molecular analyses and design for the stabilization of therapeutic proteins,” Department of Chemical Engineering, Cornell University, Ithaca, New York.
March, 2004, “Reactivity for phase transitions, zeolites, and biological systems,” Department of Chemical Engineering, University of Rochester, Rochester, New York.
37. February, 2004, “Molecular analyses and design for the stabilization of therapeutic proteins,” Department of Chemical Engineering, Tsinghua University, Beijing, China.
February, 2004, “Reactivity for phase transitions, zeolites, and biological systems,” Department of Chemistry, Fudan University, Shanghai, China.
February, 2004, “Reactivity for phase transitions, zeolites, and biological systems,” Center for Atomic-Scale Materials Physics (CAMP) and Department of Physics, Technical University of Copenhagen, Copenhagen, Denmark.
2003
November, 2003, “Ordering of water in phase transitions and biological systems,” Department of Chemistry, Washington University, St. Louis, MO.
November, 2003, “Ordering of water in phase transitions and biological systems,” Department of Physics, University of Missouri, Columbus, MO.
October, 2003, “Nucleation and growth of clathrate-hydrates and ice and a new theoretical framework to address those,” Dartmouth University, Thayer School of Engineering, Dartmouth, NH.
September, 2003, “Finding reaction pathways for industrial chemical problems,” Statistical Mechanics of Rare Events, Paris, France.
September, 2003, “Analyses of reactions in acid zeolites and of proteins via nudged elastic band calculations and Car-Parrinello simulations,” CECAM Workshop on Reactivity, Lyon, France.
May, 2003, “Reactivity of acidic zeolites via quantum chemical and Car-Parrinello molecular dynamical methods,” Advances in the Understanding and Application of Catalysis, Moscow, Russia, Plenary Lecture.
April, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, Princeton University, Princeton, NJ.
April, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA.
March, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, University of Texas, Austin, TX.
March, 2003, “Reactivity of acidic zeolites via quantum chemical and Car-Parrinello molecular dynamical methods,” invited talk in “Mechanistic Surface Chemistry,” Spring Meeting of the American Chemical Society, New Orleans, LA.
March, 2003, “Effects of solvation on biological processes,” invited talk in “Symposium in Honor of Professor Clayton J. Radke, recipient of the American Chemical Society Award in Colloid Chemistry,” Spring Meeting of the American Chemical Society, New Orleans, LA.
March, 2003, February, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, Stanford University, Palo Alto, CA.
February, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, Tsinghua Univeristy, Beijing, China.
February, 2003, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, North Carolina State University, Raleigh, NC.
2002
November, 2002, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, University of California, Berkeley, CA.
November, 2002, “Solvation effects in clathrate-hydrates and biological systems,” Department of Chemical Engineering, California Institute of Technology, Pasadena, CA.
July, 2002, “Nucleation of and transport in clathrate-hydrates and ice,” Physics and Chemistry of Ice Conference, New Foundland, Canada.
June 2002, “Quantum mechanical calculations applied to engineering problems,” Steacie Institute of Molecular Sciences, National Research Council, Ottawa, Ontario, Canada.
April, 2002, “Molecular simulations for the stabilization of therapeutic proteins and the quantification of nucleation of clathrate-hydrates,” Rensselaer Polytechnic Institute, Troy, NY.
April, 2002, “Quantification of reactive sites in zeolitic and transition metal catalysts via first-principles,” ACS Meeting, Orlando, Fl.
February, 2002, “The identification and study of sites of varying activity in zeolites and transition metal catalysts,” First-Principles Catalysis, Vienna, Austria.
February, 2002, “Order-disorder transitions on the surface of ice and in bulk ice and clathrate-hydrates,” Swiss Center for Computational Sciences, Manno, Switzerland.
February, 2002, “Molecular simulations for the stabilization of therapeutic proteins and the quantification of nucleation of clathrate-hydrates,” Colorado School of Mines, Golden, CO.
2001
August, 2001, “Car-Parrinello simulations of the disordering of ice and dissociation of HCl, relevant to stratospheric chemistry,” ACS Meeting, Chicago, IL.
July, 2001, “Insight into the stabilization of therapeutic proteins via molecular simulations,” National University of Singapore, Singapore.
June, 2001, “Insight into the stabilization of therapeutic proteins via molecular simulations,” Hong Kong University of Science and Technology, Hong Kong.
April, 2001, “Multi-scale modeling of hydrate-clathrates from first-principles to macroscopic thermodynamics,” University of Connecticut, Storrs, CT.
February, 2001, “Multi-scale modeling of hydrate-clathrates from first-principles to macroscopic thermodynamics,” Georgia Institute of Technology, Atlanta, GA.
January, 2001, “Multi-scale modeling of hydrate-clathrates from first-principles to macroscopic thermodynamics,” National University of Singapore, Singapore.
1999 - 1996
1999
November 1999, “Sustainable development,” TBΠ Leonardo Lecture, MIT.
June, 1999, “Application of molecular modeling to automotive catalysis,” Workshop held at Ford Motor Company, Dearborn.
March, 1999, “Defect structure and its relation to methanol activation”, ACS Annual Conference, Annaheim, CA.
1998
April, 1998, “Quantum mechanical methods in catalysis: a primer”, New England Catalysis Society, Worchester, MA.
1996
September, 1996, “Dynamic Monte Carlo study of reaction and diffusion sites in ZSM-5 Zeolites”, Technical University of Athens, Athens, Greece.
